Search: 
You do not have permission to access this chart.
Please Sign Up or Login
News for Tarsus Pharmaceuticals, Inc. (TARS)
Newly released Crypto mining rig for Tarsus Pharmaceuticals, Inc. coins
minutes ago | Banggood.com
Everything Crypto on sale now!
58 minutes ago | Aliexpress.com
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors
3 days ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
a week ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
3 weeks ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
a month ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference
a month ago | GlobeNewsWire
Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study
a month ago | Benzinga
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis
a month ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
a month ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
a month ago | GlobeNewsWire
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
2 months ago | GlobeNewsWire

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

18

Address:

Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road Suite 160 Irvine CA 92618 United States

Website:

Home

Phone:

949-409-9820

Leave a comment

Your email address will not be published. Required fields are marked *